Darcy A. Hille
Merck & Co.
64 Papers
547 Citations
Darcy A. Hille is an academic researcher from Merck & Co.. The author has contributed to research in topics: Left ventricular hypertrophy & Medicine. The author has an hindex of 29, co-authored 60 publications. Previous affiliations of Darcy A. Hille include United States Military Academy & Cornell University.
Chat about Author
Papers
Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy
Peter M. Okin,Casper N. Bang,Kristian Wachtell,Darcy A. Hille,Sverre E. Kjeldsen,Björn Dahlöf,Richard B. Devereux +6 more
TL;DR: Development of new-onset AF identifies hypertensive patients at increased risk of SCD, and is associated with a higher sudden cardiac death (SCD) rate in some populations.
72
Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States.
Susan E. Coffin,Joseph Elser,Colin D. Marchant,Mark H. Sawyer,Bernard Pollara,Ruby Fayorsey,Linda Nelson,Diane Lawley,Michelle G. Goveia,Jon E. Stek,Darcy A. Hille,Mark J. DiNubile +11 more
TL;DR: In this multicenter study, rotavirus consistently caused a sizable proportion of cases of acute gastroenteritis seen in pediatric outpatient practices in the United States during the winter and spring.
68
Impact of lower achieved blood pressure on outcomes in hypertensive patients.
TL;DR: The need for randomized evaluation of treatment to more aggressive vs. conventional SBP targets is supported, aschieved SBP 130 mmHg or less is not associated with lower cardiovascular risk and is associated with a significantly increased risk of death and trend towards increased cardiovascular mortality.
64
Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension
TL;DR: Persistence or development of ECG LVH by both Cornell product and Sokolow‐Lyon voltage criteria during antihypertensive therapy is associated with markedly increased risks of cardiovascular end points and all‐cause mortality.
63
Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
TL;DR: Underlying cancers, most commonly leukaemias and gastrointestinal tumors, were present in one-third of patients enrolled in this study of invasive candidiasis, and 70% of caspofungin-treated and 56% of amphotericin B-treated cancer patients responded favorably.
57